We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $1.85M
1-Year Est. Return 176.16%
This Fund
S&P 500
This Quarter Est. Return
+6.07%
1 Year Est. Return
+176.16%
3 Year Est. Return
+511.75%
5 Year Est. Return
+854.95%
10 Year Est. Return
+8,566.11%
AUM
$4.02M
AUM Growth
-$255K
Cap. Flow
-$384K
Cap. Flow %
-9.53%
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
2
Reduced
–
Closed
5

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$295K
2
ALXO icon
ALX Oncology
ALXO
+$39.9K
3
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$8.35K

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$292K
2
DFTX
Definium Therapeutics
DFTX
+$210K
3
CMPX icon
Compass Therapeutics
CMPX
+$158K
4
SABS icon
SAB Biotherapeutics
SABS
+$39.4K
5
CNTX icon
Context Therapeutics
CNTX
+$27.1K

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.5%
2 Healthcare 9.84%
3 Financials 8.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLD icon
1
SPDR Gold Trust
GLD
$154B
$3.28M 81.5%
7,623
+659
+9% +$295K
BRK.B icon
2
Berkshire Hathaway Class B
BRK.B
$1.08T
$348K 8.66%
727
+17
+2% +$8.35K
KYTX icon
3
Kyverna Therapeutics
KYTX
$534M
$162K 4.03%
18,773
– –
LXEO icon
4
Lexeo Therapeutics
LXEO
$409M
$80K 1.99%
13,943
– –
XFOR icon
5
X4 Pharmaceuticals
XFOR
$417M
$64.2K 1.6%
15,557
– –
IKT icon
6
Inhibikase Therapeutics
IKT
$346M
$47.8K 1.19%
28,453
– –
ALXO icon
7
ALX Oncology
ALXO
$282M
$42K 1.04%
+20,946
New +$39.9K
CMPX icon
8
Compass Therapeutics
CMPX
$447M
– –
-29,495
Closed -$158K
CNTX icon
9
Context Therapeutics
CNTX
$37.9M
– –
-18,403
Closed -$27.1K
DFTX
10
Definium Therapeutics
DFTX
$5.91B
– –
-15,688
Closed -$210K
SABS icon
11
SAB Biotherapeutics
SABS
$357M
– –
-10,527
Closed -$39.4K
SYRE icon
12
Spyre Therapeutics
SYRE
$8.26B
– –
-8,919
Closed -$292K

Similar funds

1IC
1922 Investment Company Houston, Texas $1.89M AUM 15.39% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $1.91M AUM 81.42% 1-Year Est. Return
HGCK
HPC Germany & Co KG Potsdam, Germany $1.68M AUM 15.3% 1-Year Est. Return
CA
Cohalo Advisory Snoqualmie, Washington $1.65M AUM 11.44% 1-Year Est. Return
CAM
Creekmur Asset Management Morton, Illinois $2.07M AUM
FLC
Fifth Lane Capital Austin, Texas $1.63M AUM 7.3% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $1.56M AUM 25.68% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Caxton Corporation's Q1 2026 Portfolio in Review

As of Q1 2026, Caxton Corporation held 12 positions worth $4.02M, down 6% from $4.28M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation withdrew a net $384K in Q1 2026, closing 5 positions. Its most notable exit was Spyre Therapeutics, an estimated $292K position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 82% of assets, up from 64% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Caxton Corporation opened a new position in ALX Oncology worth $42K.

  • Caxton Corporation's largest Q1 2026 buy was ALX Oncology: 20,946 shares worth $42K.
  • Caxton Corporation added most to SPDR Gold Trust in Q1 2026, an estimated $295K increase.
  • Caxton Corporation fully exited Spyre Therapeutics in Q1 2026, selling an estimated $292K.
  • Caxton Corporation's ten largest holdings make up 100% of its $4.02M portfolio in Q1 2026.
  • Caxton Corporation opened 1 new position and closed 5 in Q1 2026.
  • Caxton Corporation's portfolio value fell 6% quarter-over-quarter to $4.02M.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.